BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
6.76
-0.04 (-0.59%)
At close: Feb 13, 2026, 4:00 PM EST
6.81
+0.05 (0.74%)
After-hours: Feb 13, 2026, 7:58 PM EST
BioCryst Pharmaceuticals Employees
BioCryst Pharmaceuticals had 580 employees as of December 31, 2024. The number of employees increased by 44 or 8.21% compared to the previous year.
Employees
580
Change (1Y)
44
Growth (1Y)
8.21%
Revenue / Employee
$1,034,166
Profits / Employee
-$15,136
Market Cap
1.68B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 580 | 44 | 8.21% |
| Dec 31, 2023 | 536 | 5 | 0.94% |
| Dec 31, 2022 | 531 | 173 | 48.32% |
| Dec 31, 2021 | 358 | 112 | 45.53% |
| Dec 31, 2020 | 246 | 106 | 75.71% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,700 |
| Perrigo Company | 8,379 |
| Evotec SE | 4,788 |
| Phibro Animal Health | 2,475 |
| Amphastar Pharmaceuticals | 2,028 |
| HUTCHMED (China) | 1,780 |
| Alvotech | 1,012 |
| ANI Pharmaceuticals | 897 |
BCRX News
- 3 days ago - BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting - GlobeNewsWire
- 9 days ago - BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 - GlobeNewsWire
- 9 days ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema - GlobeNewsWire
- 4 weeks ago - BioCryst Pharmaceuticals, Inc. (BCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range - GlobeNewsWire
- 5 weeks ago - BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - FDA expands approval of BioCryst's rare disease drug for use in young children - Reuters